









Markets
/
Stocks
/
nasdaq-ions
/

Ionis Pharmaceuticals Inc

IONS

86.500USD

+3.020+3.62%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

13.94BMarket Cap

LossP/E TTM



Ionis Pharmaceuticals Inc

86.500

+3.020+3.62%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ionis Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ionis Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 89.83.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ionis Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

3 / 392

Overall Ranking

54 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ionis Pharmaceuticals Inc Highlights

StrengthsRisks

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 20.05% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 705.14M.

Undervalued

The company’s latest PE is -53.80, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 176.98M shares, decreasing 4.54% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.04K shares of this stock.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

89.830

Target Price

+7.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ionis Pharmaceuticals Inc is 7.70, ranking 84 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 156.72M, representing a year-over-year increase of 17.12%, while its net profit experienced a year-over-year increase of 8.45%.

Score

Industry at a Glance

Previous score

7.70

Change



Financials

4.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.28

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.35

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ionis Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ionis Pharmaceuticals Inc is 7.20, ranking 152 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -53.80, which is -84.09% below the recent high of -8.56 and 0.00% above the recent low of -53.80.

Score

Industry at a Glance

Previous score

7.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Ionis Pharmaceuticals Inc is 8.09, ranking 163 out of 392 in the Biotechnology & Medical Research industry. The average price target is 87.00, with a high of 110.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

8.09

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

89.830

Target Price

+7.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Ionis Pharmaceuticals Inc

IONS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ionis Pharmaceuticals Inc is 9.61, ranking 5 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 90.76 and the support level at 78.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.20

Change

0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.912

Buy

RSI(14)

64.145

Neutral

STOCH(KDJ)(9,3,3)

83.565

Overbought

ATR(14)

2.543

Low Volatility

CCI(14)

128.054

Buy

Williams %R

1.914

Overbought

TRIX(12,20)

0.225

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

84.526

Buy

MA10

83.424

Buy

MA20

81.357

Buy

MA50

80.764

Buy

MA100

75.403

Buy

MA200

57.929

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ionis Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.27%, representing a quarter-over-quarter increase of 2.33%. The largest institutional shareholder is The Vanguard, holding a total of 16.40M shares, representing 10.13% of shares outstanding, with 1.42% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

23.69M

+0.19%

Capital World Investors

17.96M

+41.17%

The Vanguard Group, Inc.

Star Investors

16.44M

-1.41%

T. Rowe Price Investment Management, Inc.

13.16M

-18.02%

BlackRock Institutional Trust Company, N.A.

8.45M

-3.12%

Wellington Management Company, LLP

6.59M

+3.83%

Bellevue Asset Management AG

6.24M

-20.49%

State Street Investment Management (US)

4.39M

-3.13%

Deep Track Capital LP

3.81M

-22.15%

Two Sigma Investments, LP

3.65M

-18.11%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ionis Pharmaceuticals Inc is 8.34, ranking 5 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.